



Anatara Human Health Update

MELBOURNE, 8 December 2020: Anatara Lifesciences (ASX: ANR) is pleased to advise that it is planning initiation of a human clinical study on changes to psychological functioning in adults with a moderate level of depression, anxiety or stress symptoms, in response to use of the Company's recently developed colon-targeted formulation (3FDC).

Anatara has been awarded an Innovation Connections Grant, under the Australian Government's Entrepreneurs' Programme, with funding to be provided to the Commonwealth Scientific and Industrial Research Organisation (CSIRO). This planned study is to be conducted at the CSIRO Nutrition and Health Research Clinic in Adelaide, South Australia. An update will be provided once the timeline for the study is finalised.

3FDC is a subset of Anatara's **Gastrointestinal Re-Programming (GaRP)** complementary medicine and contains ingredients that are known to have broad ranging effects in the gastrointestinal tract and systemically, including modulation of the gut-brain axis. The proposed study is to evaluate whether ANR03 delivered to the colon effects psychological functioning, specifically assessing for potential improvement in symptoms of anxiety, depression and stress.

CEO Steve Lydeamore commented, "In GaRP we have may have a portfolio in a product. During GaRP pre-clinical research, Anatara evaluated ingredients individually and in permutations to evaluate modulation within the gastrointestinal tract of gut dynamics, including immune considerations and the microbiome. Furthermore, the broad ranging effect of metabolites is increasingly considered to influence the so-called gut-brain axis. The proposed psychological functioning study will evaluate anxiety, depression and stress to assess changes to neuroactivity with the use of 3FDC".

Anatara has developed GaRP to address the unmet need for sufferers of IBS (Irritable Bowel syndrome) and IBD (Inflammatory Bowel disease). Anatara anticipates commencing in early 2021 an adaptive, randomised, double-blinded, placebo-controlled virtual clinical trial in IBS. The Company considers that future opportunities for evaluation may include functional constipation, functional diarrhoea and functional dyspepsia. Diagnostic criteria were met for at least one functional gastrointestinal disorder by 40.3% in an international survey.¹

CEO Steve Lydeamore commented, "As previously announced, Anatara is discussing licensing and commercialisation of GaRP with global consumer health companies. Information about the new potential use of 3FDC, a subset of GaRP, will now be made available to these companies. The revised timeline to a GaRP partnering deal is now H1, calendar 2021. Preliminary results of the GaRP IBS trial are anticipated in June 2021."

Anatara Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anatara.com | Website anataralifesciences.com



For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anataro Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anataro.com	Sue MacLeman Chair, Anataro Lifesciences Ltd +61 (0) 437 211 200 smacleman@anataro.com

About Anataro Lifesciences Ltd

Anataro Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataro is a life sciences company with expertise in developing products for animal and human health. Anataro is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Anataro's Gastrointestinal ReProgramming (GaRP) dietary supplement

Anataro's GaRP complementary medicine is being developed to specifically target two human gastrointestinal disorders, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). IBS is the most common GI condition affecting approximately 11% of the global population² while IBD affects an estimated five million people globally.³

Current pharmaceutical treatments have high failure rates and severe side-effects, leading to over 50% of IBS⁴ and IBD⁵ patients trying complementary and alternative medicines (CAMs) in the hope of effectively managing their chronic bowel condition. As many patients and healthcare providers believe the risk benefit of CAMs to be favourable, patients are willing to invest in their health, with this market segment being significant. In 2018, expenditure on gastrointestinal supplements and OTC digestive remedies in the US alone was US\$8 billion.^{6,7}

¹ Sperber et. al. Gastroenterology 2020; 1–16 .

² Clinical Gastroenterology and Hepatology 2012; 10, 712-721.

³ Crohn's and Colitis Australia.

⁴ Grundmann O & Yoon S (2014) World J. Gastroenterol 20 (2). p.346.

⁵ Lovell R & Ford A (2012) Clin. Gastroenterol. Hepatol. 10. p.712

⁶ Mintel's 2018 Digestive Health U.S., July 2019.

⁷ 2018 category insight Report: follow your gut-a global look at Digestive Health Products.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anataro Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anataro Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anataro.com | Website anatarolifesciences.com

